Affymetrix said today it will postpone consideration of Thermo Fisher Scientific’s $1.3 billion acquisition offer for a week while considering a revised offer made for the company yesterday by Origin ...

Mindy Lee-Olsen, 408-731-5523 (Media)Vice President, Marketing ServicesorDoug Farrell, 408-731-5285 (Investors)Vice President, Investor Relations (NASDAQ:AFFX) announced today the availability of ...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- Affymetrix, Inc. (NASDAQ: AFFX) today announced that it has delivered the first custom array designed for a 100,000-sample genotyping project to be performed ...

Some of the smart-money investors are increasingly placing their bets on the nation’s healthcare and life-sciences space where they expect more mergers-and-acquisitions deals will likely take place.

SANTA CLARA, Calif.--(BUSINESS WIRE)-- Affymetrix, Inc. (NAS: AFFX) announced the launch of the new OncoScan™ FFPE Assay Kit, a whole-genome copy number assay for highly degraded FFPE solid tumor ...

SANTA CLARA, Calif.--(BUSINESS WIRE)--Affymetrix, Inc., (NASDAQ:AFFX) announced today that it has acquired substantially all the assets of Hercules, CA-based Eureka Genomics ® Corporation for $15 ...

WILMINGTON, Delaware --A federal jury of eight will continue on Friday deliberations begun late Thursday on Oxford Gene Technology's allegation that Affymetrix's (AFFX) GeneChip product infringes on ...

SAN DIEGO & SANTA CLARA, Calif., Jan 10, 2008 - Affymetrix and Illumina, Inc. (NASDAQ:ILMN) announced today that they have entered into a settlement agreement to resolve their patent litigation. Under ...

SANTA CLARA, Calif.--(BUSINESS WIRE)--Affymetrix, Inc. (Nasdaq: AFFX) today announced that Dr. Frank Witney has been appointed president and chief executive officer, effective July 1, 2011. Dr. Witney ...

(NASDAQ: AFFX) today announced the expansion of its license agreement with Siemens Healthcare Diagnostics for the company’s branched DNA (bDNA) technology whereby Affymetrix is the exclusive licensee ...